Skip to main content

Research Article Details

Peer-Reviewed Open Access Publication · ISSN: 2321-8681 · CC-BY 4.0 International

Open Access ISSN: 2321-8681 Volume-9, Issue-1 (January-June) 2022

Review On Mab’s boon for Covid – 19

Authors: Kale Rohit, Solanke Shrikant, Dr. Deshmukh Tejeswini India
Correspondence: rohit.kale242@gmail.com

Abstract

Covid 19 virus called severe acute respiratory syndrome (SARS-CoV-2) contains spike proteins that assist the virus in entering host cells. Scientific community from the entire world is working to find an effective treatment for SARS-CoV-2. By using modern biotechnology treatment, monoclonal antibodies (MAbs) are being designed and developed to block a particular pathway of SARS-CoV-2 infection.. Many of them target the receptor binding protein so that the interaction between virus and host cell can be prevented.

Journal Research and Reviews in Biotechnology and Biosciences
Peer Review Double-Blind Peer Reviewed
Publication Year 2022
Volume Volume-9, Issue-1 (January-June)
Cite this Article

Select a citation style to copy or import directly into your reference manager:

Kale Rohit, Solanke Shrikant, Dr. Deshmukh Tejeswini (2022). Review On Mab’s boon for Covid – 19. Research and Reviews in Biotechnology and Biosciences, Volume-9, Issue-1 (January-June). https://doi.org/10.5281/zenodo.6620700
Kale Rohit, Solanke Shrikant, Dr. Deshmukh Tejeswini, 2022. Review On Mab’s boon for Covid – 19. Research and Reviews in Biotechnology and Biosciences, Volume-9, Issue-1 (January-June).
Kale Rohit, Solanke Shrikant, Dr. Deshmukh Tejeswini. "Review On Mab’s boon for Covid – 19." Research and Reviews in Biotechnology and Biosciences Volume-9, Issue-1 (January-June) (2022).
@article{rrbb_199_KaleRohit, title = {{Review On Mab’s boon for Covid – 19}}, author = {Kale Rohit, Solanke Shrikant, Dr. Deshmukh Tejeswini}, journal = {Research and Reviews in Biotechnology and Biosciences}, issn = {2321-8681}, year = {2022}, volume = {Volume-9, Issue-1 (January-June)}, doi = {https://doi.org/10.5281/zenodo.6620700} }
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source.